NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Forecast, Price & News $2.76 -0.08 (-2.82%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$2.76▼$3.0050-Day Range$2.76▼$11.8552-Week Range$2.76▼$34.13Volume497,073 shsAverage Volume1.39 million shsMarket Capitalization$80.79 millionP/E RatioN/ADividend YieldN/APrice Target$23.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability BioXcel Therapeutics MarketRank™ ForecastAnalyst RatingHold2.43 Rating ScoreUpside/Downside765.0% Upside$23.88 Price TargetShort InterestHealthy21.80% of Float Sold ShortDividend StrengthN/ASustainability-1.13Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.75) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.77 out of 5 starsMedical Sector117th out of 964 stocksPharmaceutical Preparations Industry35th out of 441 stocks 4.2 Analyst's Opinion Consensus RatingBioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.88, BioXcel Therapeutics has a forecasted upside of 765.0% from its current price of $2.76.Amount of Analyst CoverageBioXcel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted21.80% of the float of BioXcel Therapeutics has been sold short.Short Interest Ratio / Days to CoverBioXcel Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioXcel Therapeutics has recently decreased by 34.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioXcel Therapeutics has received a 69.42% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for cancer", "Basic medical research services", and "Clinical research services for psychotic disorders" products. See details.Environmental SustainabilityThe Environmental Impact score for BioXcel Therapeutics is -1.13. Previous Next 2.0 News and Social Media Coverage News SentimentBioXcel Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioXcel Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 11 people have searched for BTAI on MarketBeat in the last 30 days. This is a decrease of -35% compared to the previous 30 days.MarketBeat Follows8 people have added BioXcel Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders35.80% of the stock of BioXcel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions90.86% of the stock of BioXcel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($5.75) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioXcel Therapeutics has a P/B Ratio of 1.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioXcel Therapeutics (NASDAQ:BTAI) StockBioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.Read More BTAI Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTAI Stock News HeadlinesSeptember 18, 2023 | americanbankingnews.comReviewing Vivesto (OTCMKTS:OASMY) and BioXcel Therapeutics (NASDAQ:BTAI)September 8, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Bioxcel Therapeutics (BTAI), KalVista Pharmaceuticals (KALV)September 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 5, 2023 | stockhouse.comFINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in BioXcel Therapeutics, Inc. with Losses of $100,000 to Contact the FirmSeptember 2, 2023 | prnewswire.comBTAI DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAISeptember 1, 2023 | technews.tmcnet.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioXcel Therapeutics, Inc. (BTAI)August 31, 2023 | markets.businessinsider.comROSEN, A Top Ranked Law Firm, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAIAugust 29, 2023 | markets.businessinsider.comROSEN, LEADING TRIAL ATTORNEYS, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAISeptember 27, 2023 | Stansberry Research (Ad)Bank Collapse Causes Gold Prices to SoarSilicon Valley Bank was the second-largest bank in American history to fail, and investors have started piling into the safety and security of gold. But if you're not taking advantage of a little-known way to invest for around $5 today, you're missing out.August 28, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Bioxcel Therapeutics (BTAI)August 26, 2023 | prnewswire.comBTAI CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. (BTAI) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the FirmAugust 24, 2023 | benzinga.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc. (BTAI) Investors of a Class Action Lawsuit and Upcoming DeadlineAugust 24, 2023 | benzinga.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming DeadlineAugust 23, 2023 | benzinga.comBTAI Investors Should Contact Robbins LLP About Participating in the Class Action Against BioXcel TherapeuticsAugust 23, 2023 | msn.comMizuho Reiterates BioXcel Therapeutics (BTAI) Neutral RecommendationAugust 22, 2023 | markets.businessinsider.comMizuho Securities Sticks to Their Hold Rating for Bioxcel Therapeutics (BTAI)August 19, 2023 | fool.comBioXcel Therapeutics (NASDAQ: BTAI)August 19, 2023 | prnewswire.comBIOXCEL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAIAugust 17, 2023 | prnewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioXcel Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BTAIAugust 17, 2023 | msn.comMizuho Downgrades BioXcel Therapeutics (BTAI)August 17, 2023 | finance.yahoo.comBTAI: Strategic Reprioritization Underway...August 15, 2023 | msn.comMizuho cuts BioXcel to neutral, cites reduced expectations for lead drugAugust 15, 2023 | finance.yahoo.comWhy BioXcel Therapeutics Stock Flopped Again TodayAugust 15, 2023 | uk.finance.yahoo.comFurther weakness as BioXcel Therapeutics (NASDAQ:BTAI) drops 42% this week, taking three-year losses to 90%August 15, 2023 | msn.comBioXcel Therapeutics to cut workforce 58%, stock falls 27%August 15, 2023 | markets.businessinsider.comChallenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization StrategyAugust 15, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Bioxcel Therapeutics (BTAI) and Roivant Sciences (ROIV)See More Headlines Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BTAI Company Calendar Last Earnings8/14/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BTAI CUSIPN/A CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees183Year Founded2017Price Target and Rating Average Stock Price Forecast$23.88 High Stock Price Forecast$40.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+765.0%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($7.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,760,000.00 Net Margins-19,549.52% Pretax Margin-19,549.71% Return on Equity-309.06% Return on Assets-105.30% Debt Debt-to-Equity Ratio16.52 Current Ratio3.98 Quick Ratio3.92 Sales & Book Value Annual Sales$380,000.00 Price / Sales212.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / Book1.01Miscellaneous Outstanding Shares29,270,000Free Float18,791,000Market Cap$80.79 million OptionableNot Optionable Beta1.00 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Vimal D. Mehta Ph.D. (Age 62)Founder, CEO, Pres, & Director Comp: $1.76MMr. Javier Rodriguez (Age 51)Sr. VP, Chief Legal Officer & Corp. Sec. Comp: $638.88kMr. Matthew Wiley (Age 51)Sr. VP & Chief Commercial Officer Comp: $620.12kMr. Richard I. Steinhart MBA (Age 66)Sr. VP & CFO Dr. Frank D. Yocca Ph.D. (Age 67)Sr. VP & Chief Scientific Officer Dr. Vincent J. O'Neill B.Sc. (Age 54)M.D., M.R.C.P., Sr. VP & Chief Medical Officer Dr. Chetan D. Lathia Ph.D.Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory AffairsDr. Robert Risinger M.D.Chief Medical Officer - NeuroscienceMr. Robert Scala (Age 54)VP of Commercial Operations & Launch Planning Dr. Friso PostmaSr. Director of Neuroscience & Artificial intelligenceMore ExecutivesKey CompetitorsSyros PharmaceuticalsNASDAQ:SYRSNkartaNASDAQ:NKTXAnebulo PharmaceuticalsNASDAQ:ANEBKezar Life SciencesNASDAQ:KZRVaccinexNASDAQ:VCNXView All CompetitorsInsiders & InstitutionsGoldman Sachs Group Inc.Sold 19,604 shares on 8/15/2023Ownership: 0.494%Wells Fargo & Company MNBought 29,770 shares on 8/15/2023Ownership: 0.265%Alliancebernstein L.P.Bought 11,880 shares on 8/15/2023Ownership: 0.123%Hudson Bay Capital Management LPBought 29,300 shares on 8/15/2023Ownership: 0.100%XTX Topco LtdBought 16,509 shares on 8/15/2023Ownership: 0.057%View All Insider TransactionsView All Institutional Transactions BTAI Stock - Frequently Asked Questions Should I buy or sell BioXcel Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares. View BTAI analyst ratings or view top-rated stocks. What is BioXcel Therapeutics' stock price forecast for 2023? 7 Wall Street research analysts have issued 12-month price targets for BioXcel Therapeutics' stock. Their BTAI share price forecasts range from $11.00 to $40.00. On average, they predict the company's share price to reach $23.88 in the next year. This suggests a possible upside of 765.0% from the stock's current price. View analysts price targets for BTAI or view top-rated stocks among Wall Street analysts. How have BTAI shares performed in 2023? BioXcel Therapeutics' stock was trading at $21.48 at the beginning of the year. Since then, BTAI shares have decreased by 87.2% and is now trading at $2.76. View the best growth stocks for 2023 here. When is BioXcel Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our BTAI earnings forecast. How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its earnings results on Monday, August, 14th. The company reported ($1.83) EPS for the quarter, missing the consensus estimate of ($1.72) by $0.11. The business earned $0.46 million during the quarter, compared to analyst estimates of $0.42 million. BioXcel Therapeutics had a negative net margin of 19,549.52% and a negative trailing twelve-month return on equity of 309.06%. The business's revenue was up 45600.0% on a year-over-year basis. During the same quarter last year, the business posted ($1.35) earnings per share. What ETF holds BioXcel Therapeutics' stock ? iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT). When did BioXcel Therapeutics IPO? (BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is BioXcel Therapeutics' stock symbol? BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI." Who are BioXcel Therapeutics' major shareholders? BioXcel Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (7.11%), BlackRock Inc. (4.76%), Artemis Investment Management LLP (3.07%), Geode Capital Management LLC (1.39%), Northern Trust Corp (0.84%) and Point72 Asset Management L.P. (0.83%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart, Vimal Mehta and Vincent O'neill. View institutional ownership trends. How do I buy shares of BioXcel Therapeutics? Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioXcel Therapeutics' stock price today? One share of BTAI stock can currently be purchased for approximately $2.76. How much money does BioXcel Therapeutics make? BioXcel Therapeutics (NASDAQ:BTAI) has a market capitalization of $80.79 million and generates $380,000.00 in revenue each year. The company earns $-165,760,000.00 in net income (profit) each year or ($7.11) on an earnings per share basis. How many employees does BioXcel Therapeutics have? The company employs 183 workers across the globe. How can I contact BioXcel Therapeutics? BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The official website for the company is www.bioxceltherapeutics.com. The company can be reached via phone at (475) 238-6837 or via email at jmohite@theruthgroup.com. This page (NASDAQ:BTAI) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.